Neurobiology of 3,4-methylenedioxypyrovalerone (MDPV) and α-pyrrolidinovalerophenone (α-PVP)

Brain Research Bulletin

Volumn 126, Issue , 2016, Pages 111-126

  Glennon, Richard A ^a   Young, Richard ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Behavioral studies; Mechanism of action; Metabolism; Structure activity relationships (SAR); Synthetic cathinones

Indexed keywords

3,4 METHYLENEDIOXYPYROVALERONE; ALPHA PYRROLIDINOVALEROPHENONE; AMPHETAMINE; CATHINONE; COCAINE; METHAMPHETAMINE; PYROVALERONE; UNCLASSIFIED DRUG; 1,3 BENZODIOXOLE DERIVATIVE; 3,4-METHYLENEDIOXYPYROVALERONE; ALPHA-PYRROLIDINOVALEROPHENONE; DESIGNER DRUG; PYRROLIDINE DERIVATIVE;

CATHA EDULIS; CHEMICAL STRUCTURE; DRUG DISCRIMINATION; DRUG HYDROXYLATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SCREENING; DRUG STRUCTURE; HUMAN; IN VITRO STUDY; LOCOMOTION; NEUROBIOLOGY; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; REVIEW; SPECIES DIFFERENCE; STRUCTURE ACTIVITY RELATION; THERAPEUTIC INDEX; XENOPUS LAEVIS; ANIMAL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; EXPLORATORY BEHAVIOR; INSTRUMENTAL CONDITIONING; METABOLISM;

ANIMALS; BENZODIOXOLES; CONDITIONING, OPERANT; DESIGNER DRUGS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; HUMANS; LOCOMOTION; NEUROBIOLOGY; PYRROLIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84965071563     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2016.04.011     Document Type: Review

References (85)

1. Aarde, S.A., Wright, M.J. Jr., Buczynski, M.W., Angrish, D., Parsons, L.H., Houseknecht, K.L., Dickerson, T.J., Taffe, M.A., Neuropsychopharmacology, 36:S1, 2011, S441.
2. Aarde, S.M., Huang, P.K., Creehan, K.M., Dickerson, T.J., Taffe, M.A., The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: self-administration and locomotor activity in rats. Neuropharmacology 71 (2013), 130–140.
3. Aarde, S.M., Creehan, K.M., Vandewater, S.A., Dickerson, T.J., Taffe, M.A., In vivo potency and efficacy of the novel cathinone α-pyrrolidinopentiophenone and 3,4-methylenedioxypyrovalerone: self-administration and locomotor stimulation in male rats. Psychopharmacology (Berl) 232 (2015), 3045–3055.
4. Aarde, S.M., Huang, P.K., Dickerson, T.J., Taffe, M.A., Binge-like acquisition of 3,4-methylenedioxypyrovalerone (MDPV) self-administration and wheel activity in rats. Psychopharmacology (Berl) 232 (2015), 1867–1877.
5. Adorjan, 1967. Boehringer Ingelheim GmbH. α-Aminocétones comportant un groupe amino hétérocyclique. French patent, FR5502, December 4, 1967.
6. Anizan, S., Concheiro, M., Lehner, K.R., Bukhari, M.O., Suzuki, M., Rice, K.C., Baumann, M.H., Huestis, M.A., Linear pharmacokinetics of 3,4-methylenedioxypyrovalerone (MDPV) and its metabolites in the rat: relationship to pharmacodynamic effects. Addict. Biol., 2014, 10.1111/adb.12201 (Epubaheadofprint).
7. Baumann, M.H., Partilla, J.S., Lehner, K.R., Thorndike, E.B., Hoffman, A.F., Holy, M., Rothman, R.B., Goldberg, S.R., Lupica, C.R., Sitte, H.H., Brandt, S.D., Tella, S.R., Cozzi, N.V., Schindler, C.W., Powerful cocaine like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive ‘bath salts' products. Neuropsychopharmacology 38 (2013), 552–562.
8. Boehringer Ingelheim GmbH, 1969. α-Substituted ketones and processes for their preparation. British Patent, GB 1149366, April 23, 1969.
9. Bonano, J.S., Glennon, R.A., De Felice, L.J., Banks, M.L., Negus, S.S., Abuse-related and abuse-limiting effects of methcathinone and the synthetic bath salts cathinone analogs methylenedioxypyrovalerone (MDPV), methylone and mephedrone on intracranial self-stimulation in rats. Psychopharmacology (Berl) 231 (2014), 199–207.
10. Bonano, J.S., Runyon, S.P., Hassler, C., Glennon, R.A., Negus, S.S., Effects of the neuropeptide S receptor antagonist RTI-118 on abuse-related facilitation of intracranial self-stimulation produced by cocaine and methylenedioxypyrovalerone (MDPV) in rats. Eur. J. Pharmacol. 743 (2014), 98–105.
11. Bowyer, J.F., Gough, B., Slikker, W. Jr., Lipe, G.W., Newport, G.D., Holson, R.R., Effects of a cold environment or age on methamphetamine-induced dopamine release in the caudate putamen of female rats. Pharmacol. Biochem. Behav. 44 (1993), 87–98.
12. Cameron, K., Kolanos, R., Solis, E., et al. Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter. Br J. Pharmacol. 168 (2013), 1750–1757.
13. Carroll, F.I., Blough, B.E., Abraham, P., et al. Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J. Med. Chem. 52 (2009), 6768–6781.
14. Cho, A.K., Kumagai, Y., Metabolism of amphetamine and arylisopropylamines. Cho, A.K., Segal, D.S., (eds.) Amphetamine and Its Analogs. Psychopharmacology, Toxicology, and Abuse, 1994, Academic Press, San Diego, 43–77.
15. Collier, G.H., Johnson, D.F., CyBulski, K.A., McHale, C.A., Activity patterns in rats (Rattus norvegicus) as a function of the cost of access to four resources. J. Comp. Psychol. 104 (1990), 53–65.
16. DEA (Drug Enforcement Administration, May 2013), 3,4-Methylenedioxypyrovalaerone (MDPV) (Street Names: bath salts, Ivory Wave, plant fertilizer, Vanilla Sky, Energy-1′).
17. Dafters, R.I., Hyperthermia following MDMA administration in rats: effects of ambient temperature water consumption, and chronic dosing. Physiol. Behav. 58 (1995), 877–882.
18. Daws, L.C., Irvine, R.J., Callaghan, P.D., Toop, N.P., White, J.M., Bochner, F., Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. Prog. Neuropsychopharmacol. Biol. Psychiatry 24 (2000), 955–977.
19. ECDD, 2015. 1-Phenyl-2-(pyrrolidin-1-yl)pentan-1- one (α-PVP) critical review report. Expert Committee on Drug Dependence Thirty-seventh Meeting Geneva, 16–20 November 2015. Agenda item 5.3. pp 1–32.
20. Eshleman, A.J., Wolfrum, K.M., Hatfield, M.G., et al. Substituted methcathinones differ in transporter and receptor interactions. Biochem. Pharmacol. 85 (2013), 1803–1815.
21. Fantegrossi, W.E., Gannon, B.M., Zimmerman, S.M., Rice, K.C., In vivo effects of abused ‘bath salt' constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: drug discrimination, thermoregulation, and locomotor activity. Neuropsychopharmacology 38 (2013), 563–573.
22. Fuwa, T., Fukumori, N., Tanaka, T., Kubo, Y., Ogata, A., Uehara, S., Honda, Y., Kodama, T., Microdialysis study of drug effects on central nervous system. Changes of dopamine levels in mice striatum after oral administration of methylenedioxypyrovalerone. Ann. Rep. Tokyo Metr. Inst. Pub. Health 58 (2007), 287–292.
23. Gannon, B.M., Williamson, A., Suzuki, M., Rice, K.C., Fantegrossi, W.E., Stereoselective effects of abused Bath Salt constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: drug discrimination, locomotor activity, and thermoregulation. J. Pharmacol. Exp. Ther. 356 (2016), 615–623.
24. Gatch, M.B., Taylor, C.M., Forster, M.J., Locomotor stimulant and discriminative stimulus effects of ‘bath salt' cathinones. Behav. Pharmacol. 24 (2013), 437–447.
25. Gatch, M.B., Dolan, S.B., Forster, M.J., Comparative behavioral pharmacology of three pyrrolidine-containing synthetic cathinone derivatives. J. Pharmacol. Exp. Ther. 354 (2015), 103–110.
26. Glennon, R.A., Young, R., Drug Discrimination: Applications to Medicinal Chemistry and Drug Studies. 2011, Wiley, Hoboken.
27. Glennon, R.A., Bath salts mephedrone, and methylenedioxypyrovalerone as emerging illicit drugs that will need targeted therapeutic intervention. Adv. Pharmacol. 69 (2014), 581–620.
28. Grapp, M., Sauer, C., Vidal, C., Muller, D., GC–MS analysis of the designer drug α-pyrrolidinovalerophenone and its metabolites in urine and blood in an acute poisoning case. Forensic Sci. Int 259 (2016), e14–e19.
29. Griffiths, R.R., Ator, N.A., Benzodiazepine self-administration in animals and humans: a comprehensive literature review. NIDA Res. Monogr. 33 (1980), 22–36.
30. Harvey, E.L., Baker, L.E., Differential effects of 3,4-methylenedioxypyrovalerone (MDPV) and 4-methylmethcathinone (mephedrone) in rats trained to discriminate MDMA or a d-amphetamine + MDMA mixture. Psychopharmacology (Berl) 233 (2016), 673–680.
31. Heffe, W., 1966. Verfahren zur Herstellung von α-Pyrrolidino-valerophenonen. Patent No. CH 395998. Dr. A. Wander A.G., Bern, Switzerland, January 14, 1966.
32. Heffe, W., 1966.Verfahren zur Herstellung von α-Pyrrolidino-valerophenonen. Patent No. CH 401054. Dr. A. Wander A.G., Bern, Switzerland, April 30, 1966.
33. Holliday, A.R., Morris, R.B., Sharpley, R.P., Compound 84/F 1983 compared with amphetamine and placebo in regard to effects on human performance. Psychopharmacologia 6 (1964), 192–200.
34. Huang, P.-K., Aarde, S.M., Angrish, D., Houseknecht, K.L., Dickerson, T.J., Taffe, M.A., Contrasting effects of d-methamphetamine 3,4-methylenedioxymethamphetamine, 3,4-methylenedioxypyrovalerone, and 4-methylmethcathinone on wheel activity in rats. Drug Alcohol Depend. 126 (2012), 168–175.
35. Ishigami, A., Kubo, S., Gotohda, T., Tokunaga, I., The application of immunohistochemical findings in the diagnosis in methamphetamine-related death-two forensic autopsy cases. J. Med. Invest. 50 (2003), 112–116.
36. Köppe, H., Ludwig, G., Zeile, K., 1969. Verfahren zur Herstellung von α-Aminoketonen mit heterocyclischer Aminogruppe. German patent, DE1545591, August 7, 1969.
37. Köppe, H., 1969. 1-(3′4′-Methylenedioxy-phenyl)-2-pyrrolidino-alkanones-(1). U. S Patent 3,478,050, November 11, 1969.
38. Kaizaki, A., Tanaka, S., Numazawa, S., New recreational drug 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone (alpha-PVP) activates central nervous system via dopaminergic neuron. J. Toxicol. Sci. 39 (2014), 1–6.
39. Karlsson, L., Andersson, M., Kronstrand, R., Kugelberg, F.C., Mephedrone methylone and 3, 4-methylenedioxypyrovalerone (MDPV) induce conditioned place preference in mice. Basic Clin. Pharmacol. Toxicol. 115 (2014), 411–416.
40. King, H.E., Wetzell, B., Rice, K.C., Riley, A.L., 3,4-Methylenedioxypyrovalerone (MDPV)-induced conditioned taste avoidance in the F344/N and LEW rat strains. Pharmacol. Biochem. Behav. 126 (2014), 163–169.
41. King, H.E., Wetzell, B., Rice, K.C., Riley, A.L., An assessment of MDPV-induced place preference in adult Sprague-Dawley rats. Drug Alcohol Depend. 146 (2015), 116–119.
42. King, H.E., Wakeford, A., Taylor, W., Wetzell, B., Rice, K.C., Riley, A.L., Sex differences in 3,4-methylenedioxypyrovalerone (MDPV)-induced taste avoidance and place preferences. Pharmacol. Biochem. Behav. 137 (2015), 16–22.
43. Kiyatkin, E.A., Kim, A.H., Wakabayashi, K.T., Baumann, M.H., Shaham, Y., Effects of social interaction and warm ambient temperature on brain hyperthermia induced by the designer drugs methylone and MDPV. Neuropsychopharmacology 40 (2015), 436–445.
44. Kolanos, R., Sakloth, F., Jain, A.D., et al. Structural modification of the designer stimulant α-pyrrolidinovalerophenone (α-PVP) influences potency at dopamine transporters. ACS Chem. Neurosci. 6 (2015), 1726–1731.
45. Kolanos, R., Partilla, J.S., Baumann, M.H., Hutsell, B.A., Banks, M.L., Negus, S.S., Stereoselective actions of methylenedioxypyrovalerone (MDPV) to inhibit dopamine and norepinephrine transporters and facilitate intracranial self-stimulation in rats. ACS Chem. Neurosci. 6 (2015), 771–777.
46. Lomax, P., Daniel, K.A., Cocaine and body temperature in the rat: effects of ambient temperature. Pharmacology 40 (1990), 103–109.
47. Marusich, J.A., Grant, K.R., Blough, B.E., Wiley, J.L., Effects of synthetic cathinones contained in bath salts on motor behavior and a functional observational battery in mice. Neurotoxicology 33 (2012), 1305–1313.
48. Marusich, J.A., Antonazzo, K.R., Wiley, J.L., Blough, B.E., Partilla, J.S., Baumann, M.H., Pharmacology of novel synthetic stimulants structurally related to the bath salts constituent 3,4-methylenedioxypyrovalerone (MDPV). Neuropharmacology 87 (2014), 206–213.
49. Mason, G.J., Stereotypies: a critical review. Anim. Behav. 41 (1991), 1015–1037.
50. Matsuta, S., Shima, N., Kamata, H., Kakehashi, H., Nakano, S., Sasaki, K., Kamata, T., Nishioka, H., Miki, A., Katagi, M., Zaitsu, K., Sato, T., Tsuchihashi, H., Suzuki, K., Metabolism of the designer drug α-pyrrolidinobutiophenone (α-PBP) in humans: identification and quantification of the phase I metabolites in urine. Forensic Sci. Int. 249 (2015), 181–188.
51. Meltzer, P.C., Butler, D., Deschamps, J.R., et al. 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J. Med. Chem. 49 (2006), 1420–1432.
52. Merluzzi, A.P., Hurwitz, Z.E., Briscione, M.A., Cobuzzi, J.L., Wetzell, B., Rice, K.C., Riley, A.L., Age dependent MDPV-induced taste aversions and thermoregulation in adolescent and adult rats. Dev. Psychobiol. 56 (2014), 943–954.
53. Meyer, M.R., Du, P., Schuster, F., Maurer, H.H., Studies on the metabolism of the α-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC–MS and LC-high-resolution MS and its detectability in urine by GC–MS. J. Mass Spectrom. 45 (2010), 1426–1442.
54. Michaelis, W., Russel, J.H., Schindler, O., Metabolism of pyrovalerone hydrochloride. J. Med. Chem. 13 (1970), 497–503.
55. Myles, B.J., Jarrett, L.A., Broom, S.L., Speaker, H.A., Sabol, K.E., The effects of methamphetamine on core body temperature in the rat–part 1: chronic treatment and ambient temperature. Psychopharmacology (Berl) 198 (2008), 301–311.
56. Naylor, J.E., Freeman, K.B., Blough, B.E., Woolverton, W.L., Huskinson, S.L., Discriminative stimulus effects of second generation synthetic cathinones in methamphetamine-trained rats. Drug Alcohol Depend. 149 (2015), 280–284.
57. Negreira, N., Erratico, C., Kosjek, T., van Nuijs, A.L., Heath, E., Neels, H., Covaci, A., In vitro Phase I and Phase II metabolism of α-pyrrolidinovalerophenone (α-PVP): methylenedioxypyrovalerone (MDPV) and methedrone by human liver microsomes and human liver cytosol. Anal. Bioanal. Chem. 407 (2015), 5803–5816.
58. Nolte, K.B., Rhabdomyolysis associated with cocaine abuse. Hum. Pathol. 22 (1991), 1141–1145.
59. Pan, X., Lai, R.E., Glennon, R.A., Sweet, D.H., Potent Inhibition of Human Organic Cation Transporters 1, 2, and 3 by Synthetic Cathinones, 2–6, 2014, American Association of Pharmaceutical Sciences Annual Meeting, San Diego, California Abstract R6340 (November).
60. Panlilio, L.V., Goldberg, S.R., Self-administration of drugs in animals and humans as a model and an investigative tool. Addiction 102 (2007), 1863–1870.
61. Sauer, C., Peters, F.T., Haas, C., Meyer, M.R., Fritschi, G., Maurer, H.H., New designer drug alpha-pyrrolidinovalerophenone (PVP): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J. Mass. Spectrom. 44 (2009), 952–964.
62. Schenk, S., Hely, L., Lake, B., Daniela, E., Gittings, D., Mash, D.C., MDMA self-administration in rats: acquisition, progressive ratio responding and serotonin transporter binding. Eur. J. Neurosci. 26 (2007), 3229–3236.
63. Schindler, C.W., Thorndike, E.B., Goldberg, S.R., Lehner, K.R., Cozzi, N.V., Brandt, S.D., Baumann, M.H., Reinforcing and neurochemical effects of the bath salts constituents 3 4-methylenedioxypyrovalerone (MDPV) and 3,4-methylene-N-methylcathinone (methylone) in male rats. Psychopharmacology (Berl) 233 (2015), 1981–1990.
64. Screaton, G.R., Singer, M., Cairns, H.S., Thrasher, A., Sarner, M., Cohen, S.L., Hyperpyrexia and rhabdomyolysis after MDMA (ecstasy) abuse. Lancet 339 (1992), 677–678.
65. Seeger, E., 1964. Verfahren zur Herstellung von α-Pyrrolidinoketonen und deren Salzen. German patent 1,161,274, January 16, 1964.
66. Seeger, E., 1966. Compositions and methods for stimulating the central nervous system and increasing the blood pressure. Patent No. US 3287217. Boehringer Ingelheim GmbH, Biberach an der Riss, Germany, November 22, 1966.
67. Seeger, E., 1967. α-Pyrrolidino ketones. Patent No. US 3314970. Boehringer Ingelheim GmbH, Biberach an der Riss, Germany, April 18, 1967.
68. Sherwin, C.M., Voluntary wheel running: a review and novel interpretation. Anim. Behav. 56 (1998), 11–27.
69. Shima, N., Katagi, M., Kamata, H., Matsuta, S., Sasaki, K., Kamata, T., Nishioka, H., Miki, A., Tatsuno, M., et al. Metabolism of the newly encountered designer drug α-pyrrolidinovalerophenone in humans: identification and quantitation of urinary metabolites. Forensic Toxicol. 32 (2014), 59–67.
70. Simmler, L.D., Buser, T.A., Donzelli, M., et al. Pharmacological characterization of designer cathinones in vitro. Br. J. Pharmacol. 168 (2013), 458–470.
71. Springer, D., Fritschi, G., Maurer, H.H., Metabolism of the new designer drug alpha-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4-methyl-alpha-pyrrolidinopropiophenone (MPPP) studied in rat urine using gas chromatography-mass spectrometry. J. Chromatog. B 796 (2003), 253–266.
72. Springer, D., Fritschi, G., Maurer, H.H., Metabolism and toxicological detection of the new designer drug 3,4-methylenedioxy-α-pyrrolidinopropiophenone studied in urine using gas chromatography-mass spectrometry. J. Chromatog. B. 793 (2003), 377–388.
73. Stille, H., Ackermann, E., Eichenberger, E., Lauener, H., Vergleichende pharmakologische untersuchung eines neuen zentralen stimulans, 1-p-Tolyl-1-oxo-2-pyrrolidino-n-pentan-HC1. Arzneim. Forsch. Arzneimittel-Forsch. 18 (1963), 871–877.
74. Strano-Rossi, S., Cadwallader, A.B., de la Torre, X., Botrè, F., Toxicological determination and in vitro metabolism of the designer drug methylenedioxypyrovalerone (MPDV) by gas chromatography/mass spectrometry and liquid chromatography/quadrupole time-of-flight mass spectrometry. Rapid Commun. Mass Spect 24 (2010), 2706–2714.
75. Thomae, Karl, 1963. GmbH. α-Pyrrolidino-ketones. Patent No. GB 933507. Dr. Karl Thomae GmbH, Biberach an der Riss, Germany, August 8, 1963.
76. Tyrkkö, E., Pelander, A., Ketola, R.A., Ojanperä, I., In silico and in vitro metabolism studies support identification of designer drugs in human urine by liquid chromatography/quadrupole-time-of-flight mass spectrometry. Anal. Bioanal. Chem. 405 (2013), 6697–6709.
77. Uralets, V., Rana, S., Morgan, S., Ross, W., Testing for designer stimulants: metabolic profiles of 16 synthetic cathinones excreted free in human urine. J. Anal. Toxicol. 38 (2014), 233–241.
78. Van Abeelen, J.H.F., Mouse mutants studied by means of ethological methods I. Ethogram. Genetica 34 (1963), 79–94.
79. Vlachou, S., Markou, A., Intracranial Self-stimulation: Animal Models of Drug Addiction. 2011, Humana Press, New York.
80. Wakabayashi, K.T., Res, S.E., Kiyatkin, E.A., Methylenedioxypyrovalerone (MDPV) mimics cocaine in its physiological and behavioral effects but induces distinct changes in NAc glucose. Front. Neurosci. 9 (2015), 1–14.
81. Wander, A. 1963. S.A. α-Pyrrolidino-valerophenones. Patent No. GB 927475. Dr. A. Wander S.A, Bern, Switzerland, May 29, 1963.
82. Watterson, L.R., Kufahl, P.R., Nemirovsky, N.E., Sewalia, K., Olive, M.F., Potent reinforcing effects of the synthetic cathinone methylenedioxypyrovalerone (MDPV) in rats. Neuropsychopharmacology 36:S1 (2011), S440–S441.
83. Watterson, L.R., Burrows, B.T., Hernandez, R.D., Moore, K.N., Grabenauer, M., Marusich, J.A., Olive, M.F., Effects of α-pyrrolidinopentiophenone and 4-methyl-N-ethylcathinone two synthetic cathinones commonly found in second-generation bath salts, on intracranial self-stimulation thresholds in rats. Int. J. Neuropsychopharmacol. 18 (2014), 1–7.
84. Watterson, L.R., Kufahl, P.R., Nemirovsky, N.E., Sewalia, K., Grabenauer, M., Thomas, B.F., Marusich, J.A., Wegner, S., Olive, M.F., Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV). Addict. Biol. 19 (2014), 165–174.
85. World Anti-Doping Agency, List of Prohibited Substances and Methofs Cathinone and Its Analogues (e.g. Mephedrone, Methedrone, α-pyrrolidinovalerophenone). 2016 http://list.wada-ama.org/list/s6-stimulants/cathinone-and-its-analogues-e-g-mephedrone-methedrone-%CE%B1-pyrrolidinovalerophenone/.